Company profile
Radiopharm Theranostics Limited
Pipeline7 assets
- 18F-PivalateRAD 101 / FASN (Fatty acid synthase) / Small Molecule Radiopharmaceutical / DiagnosticsBrain metastases from solid tumors (Imaging)Phase 2bEnrollingUS
- 177Lu-RAD202RAD 202 / HER2 / Nanobody Radiotherapeutic / OncologyHER2-positive advanced solid tumorsPhase 1ActiveUSGlobal
- 177Lu-RAD204RAD 204 / PD-L1 / Nanobody Radiotherapeutic / OncologyPD-L1 positive advanced solid tumorsPhase 1ActiveUSGlobal
- 68Ga-TrivehexinRAD 301 / αvβ6-integrin / Peptide Radiopharmaceutical / DiagnosticsLoco-regional pancreatic cancer (Imaging)Phase 2ActiveGlobal
- 177Lu-D0301RAD 302 / αvβ6-integrin / Peptide Radiotherapeutic / OncologySolid tumors (PDAC, NSCLC, HNSCC)PreclinicalActiveGlobal
- BetaBartRV-01 / B7-H3 / Radiotherapeutic / OncologyB7H3-expressing solid tumorsPhase 1/2aActiveUS
- 161Tb-RAD 402RAD 402 / KLK3 (PSA) / Monoclonal Antibody Radiotherapeutic / OncologyAdvanced prostate cancerPhase 1ActiveAustralia
Latest news6 items
All newsRadiopharm Theranostics Announces Positive Phase 2b Trial Resultsof RAD 101 for Diagnosis of Brain Metastases
Loading Viewer…
Trial Results • Phase 2
RAD Presentation July 2026
Download presentation Loading Viewer…
RAD Presentation June 2026
Download presentation Loading Viewer…
Zacks Small-Cap Research 2026
Loading Viewer…
RAD Presentation March 2026
Download presentation Loading Viewer…